Thema: US68621F1021
ORGO, US68621F1021
iphone-5183942_1920.jpg - Foto: THN
Organogenesis stock holds at EUR 0.73 ahead of Nov. 5 results
Organogenesis stock is unchanged before the company reports third-quarter results on November 5. New clinical data supports PuraPly AM.
ad-hoc-news.de, heute 03:00 Uhr
ORGO, US68621F1021
Organogenesis stock: Organogenesis published PREPARE results. ...
PREPARE showed a 12-week benefit October 12, 2026. Organogenesis stock faces November 5, 2026 results after USD 42.80 million second-quarter revenue.
ad-hoc-news.de, 23.10.26 02:38 Uhr
ORGO, US68621F1021
Two ratings put Organogenesis stock at a USD 2.00 average ...
Organogenesis stock is down 80.41 percent year to date on October 20, 2026. It costs EUR 0.92 on October 20, 2026 at 9:41 p.m. CEST.
ad-hoc-news.de, 20.10.26 21:48 Uhr
ORGO, US68621F1021
Organogenesis stock last at USD 1.00 on October 16 down ...
Results are due November 5, 2026. Organogenesis stock last stood at USD 1.00 on October 16, 2026, down 9.91 percent versus the prior close of USD 1.11.
ad-hoc-news.de, 17.10.26 18:40 Uhr
ORGO, US68621F1021
Organogenesis stock at USD 1.11 0.90 percent above its low ...
Results are set for November 5, 2026. Organogenesis stock costs EUR 0.99 on October 15, 2026 at 9:05 p.m. CEST, down 2.54 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 21:09 Uhr
ORGO, US68621F1021
Organogenesis lowered 2026 guidance. Organogenesis stock ...
Q2 revenue was USD 43.76 million versus USD 54.27 million consensus. Organogenesis stock costs EUR 1.14 on October 8, 2026 versus EUR 1.17.
ad-hoc-news.de, 08.10.26 19:48 Uhr
ORGO, US68621F1021
FDA accepts Organogenesis BLA for Amnuvx: what it means ...
Revenue fell 58.00 percent to USD 42.80 million in the second quarter. For Organogenesis stock this means 2026 guidance of USD 179.00-215.00 million.
ad-hoc-news.de, 05.10.26 05:24 Uhr
